Article citationsMore >>

Lewis, M. A., & Hobday, T.J. (2012). Treatment of neuroendocrine tumor liver metastases. International Journal of Hepatology, 1-12.

has been cited by the following article:

Article

Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary

1Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA

2Division of Hematology and Oncology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA


American Journal of Medical Case Reports. 2019, Vol. 7 No. 7, 135-137
DOI: 10.12691/ajmcr-7-7-4
Copyright © 2019 Science and Education Publishing

Cite this paper:
Odeth Barrett-Campbell, Joselle Cook, Jordonna Brown, Evelyn Taiwo, Samy I. McFarlane. Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary. American Journal of Medical Case Reports. 2019; 7(7):135-137. doi: 10.12691/ajmcr-7-7-4.

Correspondence to: Samy  I. McFarlane, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. Email: Samy.mcfarlane@downstate.edu

Abstract

While tumor lysis syndrome is a relatively common oncologic emergency that may occur spontaneously or resulting from cancer directed therapy, it is relatively unusual occurrence in solid tumors, especially neuroendocrine tumors. It is also particularly rare after hepatic trans-arterial embolization. We report a case of a 60-year-old man who had hepatic trans-arterial embolization for metastatic neuroendocrine tumor of the liver of unknown primary, who developed tumor lysis along with post-embolization syndrome. He received aggressive intravenous fluid resuscitation, allopurinol and rasburicase for his tumor lysis syndrome but subsequently had acute renal failure for which he underwent renal replacement therapy. The patient responded well to treatment with complete resolution of his post-embolization syndrome, tumor lysis syndrome and acute renal failure. Our case report highlights the need to consider tumor lysis syndrome in solid tumors. It should be readily recognized and treated given the associated high risk of morbidity and mortality.

Keywords